News Release 

Study examines reliability of biopsies from donated kidneys prior to transplantation

American Society of Nephrology

Highlights

  • In analyses of biopsies of deceased donor kidneys, a repeat biopsy often showed very different findings than the initial biopsy, calling into question decisions to decline an organ based on the initial biopsy findings.
  • Although the first biopsy findings were not associated with post-transplant outcomes, findings from the second biopsies--which were performed in a relatively standardized manner at one organ procurement organization and read by the same group of pathologists--provided useful information about how well the organ functioned after transplantation.

Washington, DC (January 23, 2020) -- A new study indicates that biopsies of donated kidneys are likely not useful for assessing organ quality prior to transplantation unless standards are set for how they should be performed and interpreted. The findings appear in an upcoming issue of CJASN.

There is currently a large shortage of donated kidneys that leads to the death of many patients with kidney failure in need of a transplant; however, 1 out of every 5 kidneys recovered for the purpose of transplantation is not transplanted, largely due to concerns over organ quality that often stem from the results of a biopsy.

To determine whether a donated kidney is suitable for transplantation, clinicians often examine biopsy samples from the kidney under a microscope. Prior studies have shown mixed results about whether these findings are actually reliable, however.

To look into the issue, a team led by S. Ali Husain, MD, MPH and Sumit Mohan, MD, MPH (Columbia University Irving Medical Center) conducted a study of 606 kidneys that had 2 separate biopsies performed. The researchers found that the results were often quite different between the biopsies, and that only the second biopsies yielded useful information about kidney quality that correlated with how well the organ functioned after transplantation. Kidneys that underwent multiple biopsies were overwhelmingly first biopsied at other organ procurement organizations, whereas almost all of the second biopsies were performed and interpreted at the investigators' local organ procurement organization.

"These findings suggest that current decision-making about kidney quality may often be based on misleading information, but that standardizing biopsy techniques may result in more helpful biopsies," said Dr. Husain.

###

Study co-authors include Kristen L. King, MPH, Ibrahim Batal, MD, Geoffrey K. Dube, MD, Isaac E. Hall, MD, Corey Brennan, MPH, M. Barry Stokes, MD, R. John Crew, MD, Dustin Carpenter, MD, Hector Alvarado Verduzco, MD, Raphael Rosen, MD, Shana Coley, MD, Eric Campenot, MD, Dominick Santoriello, MD, Adler Perotte, MD, PhD, Karthik Natarajan, PhD, Vivette D. D'Agati, MD, David J. Cohen, MD, Lloyd E. Ratner, MD, and Glen Markowitz, MD.

Disclosures: Dr. Husain reports funding from the National Kidney Foundation and the National Center for Advancing Translational Sciences. Dr. Mohan reports being a scientific advisory board member of Angion Pharmaceutical and funding from the NIH.

The authors reported no other financial disclosures.

The article, entitled "Reproducibility of Deceased Donor Kidney Procurement Biopsies," will appear online at http://cjasn.asnjournals.org/ on January 23, 2020, doi: 10.2215/CJN.09170819.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, the American Society of Nephrology (ASN) has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit http://www.asn-online.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.